vs

Side-by-side financial comparison of Pathfinder Bancorp, Inc. (PBHC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.8M, roughly 1.1× Pathfinder Bancorp, Inc.). Pathfinder Bancorp, Inc. runs the higher net margin — -52.9% vs -1398.3%, a 1345.4% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -22.6%). Pathfinder Bancorp, Inc. produced more free cash flow last quarter ($10.4M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 3.0%).

Pathfinder Bancorp, Inc. is a regional bank holding company headquartered in New York, U.S. It operates Pathfinder Bank serving the central New York market, offering retail and commercial banking services including deposit accounts, mortgages, business loans and wealth management for individual consumers and small to medium-sized enterprises.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

PBHC vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.8M
PBHC
Growing faster (revenue YoY)
RNA
RNA
+456.7% gap
RNA
434.0%
-22.6%
PBHC
Higher net margin
PBHC
PBHC
1345.4% more per $
PBHC
-52.9%
-1398.3%
RNA
More free cash flow
PBHC
PBHC
$167.3M more FCF
PBHC
$10.4M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
3.0%
PBHC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PBHC
PBHC
RNA
RNA
Revenue
$11.8M
$12.5M
Net Profit
$-5.6M
$-174.4M
Gross Margin
Operating Margin
-81.1%
-1513.5%
Net Margin
-52.9%
-1398.3%
Revenue YoY
-22.6%
434.0%
Net Profit YoY
-242.4%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBHC
PBHC
RNA
RNA
Q4 25
$11.8M
Q3 25
$13.1M
$12.5M
Q2 25
$9.3M
$3.8M
Q1 25
$12.6M
$1.6M
Q4 24
$15.3M
$3.0M
Q3 24
$13.4M
$2.3M
Q2 24
$10.7M
$2.0M
Q1 24
$11.1M
$3.5M
Net Profit
PBHC
PBHC
RNA
RNA
Q4 25
$-5.6M
Q3 25
$626.0K
$-174.4M
Q2 25
$31.0K
$-157.3M
Q1 25
$3.0M
$-115.8M
Q4 24
$3.9M
$-102.3M
Q3 24
$-4.6M
$-80.4M
Q2 24
$2.0M
$-70.8M
Q1 24
$2.1M
$-68.9M
Operating Margin
PBHC
PBHC
RNA
RNA
Q4 25
-81.1%
Q3 25
5.1%
-1513.5%
Q2 25
0.4%
-4448.7%
Q1 25
29.5%
-8360.9%
Q4 24
55.4%
-4069.6%
Q3 24
-43.1%
-4200.9%
Q2 24
23.3%
-4040.4%
Q1 24
24.3%
-2178.6%
Net Margin
PBHC
PBHC
RNA
RNA
Q4 25
-52.9%
Q3 25
4.8%
-1398.3%
Q2 25
0.3%
-4089.3%
Q1 25
23.6%
-7360.0%
Q4 24
37.7%
-3439.5%
Q3 24
-34.6%
-3441.7%
Q2 24
18.7%
-3461.8%
Q1 24
19.0%
-1943.4%
EPS (diluted)
PBHC
PBHC
RNA
RNA
Q4 25
Q3 25
$0.47
$-1.27
Q2 25
$0.47
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$0.41
$-0.65
Q2 24
$0.41
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBHC
PBHC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
$14.1M
Stockholders' EquityBook value
$122.5M
$1.9B
Total Assets
$1.4B
$2.1B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBHC
PBHC
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Total Debt
PBHC
PBHC
RNA
RNA
Q4 25
$14.1M
Q3 25
$18.7M
Q2 25
$21.0M
Q1 25
$17.6M
Q4 24
$27.1M
Q3 24
$39.8M
Q2 24
$45.9M
Q1 24
$45.9M
Stockholders' Equity
PBHC
PBHC
RNA
RNA
Q4 25
$122.5M
Q3 25
$126.3M
$1.9B
Q2 25
$124.4M
$1.2B
Q1 25
$124.9M
$1.3B
Q4 24
$121.5M
$1.4B
Q3 24
$120.2M
$1.5B
Q2 24
$123.3M
$1.2B
Q1 24
$121.8M
$830.9M
Total Assets
PBHC
PBHC
RNA
RNA
Q4 25
$1.4B
Q3 25
$1.5B
$2.1B
Q2 25
$1.5B
$1.4B
Q1 25
$1.5B
$1.5B
Q4 24
$1.5B
$1.6B
Q3 24
$1.5B
$1.6B
Q2 24
$1.4B
$1.3B
Q1 24
$1.5B
$951.5M
Debt / Equity
PBHC
PBHC
RNA
RNA
Q4 25
0.11×
Q3 25
0.15×
Q2 25
0.17×
Q1 25
0.14×
Q4 24
0.22×
Q3 24
0.33×
Q2 24
0.37×
Q1 24
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBHC
PBHC
RNA
RNA
Operating Cash FlowLast quarter
$11.7M
$-156.2M
Free Cash FlowOCF − Capex
$10.4M
$-156.9M
FCF MarginFCF / Revenue
88.1%
-1257.6%
Capex IntensityCapex / Revenue
10.7%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$18.4M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBHC
PBHC
RNA
RNA
Q4 25
$11.7M
Q3 25
$7.0M
$-156.2M
Q2 25
$-3.7M
$-199.7M
Q1 25
$5.7M
$-124.8M
Q4 24
$11.2M
$-99.9M
Q3 24
$11.8M
$-65.6M
Q2 24
$1.5M
$-65.0M
Q1 24
$504.0K
$-70.4M
Free Cash Flow
PBHC
PBHC
RNA
RNA
Q4 25
$10.4M
Q3 25
$6.9M
$-156.9M
Q2 25
$-4.0M
$-203.0M
Q1 25
$5.1M
$-128.6M
Q4 24
$9.1M
$-103.8M
Q3 24
$11.3M
$-67.3M
Q2 24
$637.0K
$-65.5M
Q1 24
$274.0K
$-71.3M
FCF Margin
PBHC
PBHC
RNA
RNA
Q4 25
88.1%
Q3 25
52.8%
-1257.6%
Q2 25
-42.6%
-5277.1%
Q1 25
40.1%
-8174.3%
Q4 24
59.9%
-3491.0%
Q3 24
84.3%
-2881.8%
Q2 24
6.0%
-3204.6%
Q1 24
2.5%
-2012.3%
Capex Intensity
PBHC
PBHC
RNA
RNA
Q4 25
10.7%
Q3 25
1.0%
5.7%
Q2 25
2.4%
86.9%
Q1 25
5.1%
238.6%
Q4 24
13.5%
131.7%
Q3 24
3.8%
72.9%
Q2 24
8.2%
26.0%
Q1 24
2.1%
25.8%
Cash Conversion
PBHC
PBHC
RNA
RNA
Q4 25
Q3 25
11.26×
Q2 25
-120.55×
Q1 25
1.92×
Q4 24
2.87×
Q3 24
Q2 24
0.76×
Q1 24
0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PBHC
PBHC

Other$5.6M47%
Banking$3.7M31%
Deposit Account$1.5M13%
Financial Service Other$1.0M9%

RNA
RNA

Segment breakdown not available.

Related Comparisons